Abstract B012: Results From the Phase 1 Dose Escalation and Dose Expansion Study of Azenosertib, a WEE1 Inhibitor, in Patients With Advanced Solid Tumors
Funda Meric-Bernstam(The University of Texas MD Anderson Cancer Center), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Natraj Reddy Ammakkanavar(Community Health Network), Deborah B. Doroshow(Icahn School of Medicine at Mount Sinai), Ryan Kendle(Santa Barbara Botanic Garden), Hirva Mamdani(Wayne State University), David S. Miller(Southwestern Medical Center), Jennifer Segar(University of Arizona), Alexander I. Spira(Virginia Cancer Specialists), Gini F. Fleming(University of Chicago Medical Center), Thejonatha Annareddy(Acadia Pharmaceuticals (United States)), Matthew L. Anderson(Institute for Molecular Medicine), Matthew Whitehurst(Hematology Oncology Associates of Fredericksburg), Dongliang Zhuang(Acadia Pharmaceuticals (United States)), Jing‐Yi Chern(Moffitt Cancer Center), Shiraj Sen(The University of Texas MD Anderson Cancer Center), Shanta Chawla(Acadia Pharmaceuticals (United States)), Cara Mathews(Brown University), Alberto A. Mendivil(Gynecologic Oncology Associates), Jianhui Ma(Arena Pharmaceuticals (United States))
Cited by 0
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*
|Journal of Clinical Oncology|2001|819